首页> 外文期刊>The Journal of Urology >Penile scarring with intracavernous injection therapy using prostaglandin E1: a risk factor analysis.
【24h】

Penile scarring with intracavernous injection therapy using prostaglandin E1: a risk factor analysis.

机译:使用前列腺素E1进行海绵体内注射治疗的阴茎瘢痕形成:危险因素分析。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: We attempted to identify risk factors for penile scarring in patients using prostaglandin E1 injection therapy. MATERIALS AND METHODS: Records of 92 patients using prostaglandin E1 therapeutically were reviewed. With statistical methods, patients with (15) and without (77) scarring were compared. RESULTS: No significant differences between the 2 groups were found regarding duration of followup, injection frequency, prostaglandin E1 dose per injection, total number of injections or total prostaglandin E1 dose. Patients with initial penile scarring did not have a significantly higher incidence of further scarring with prostaglandin E1. CONCLUSIONS: Penile scarring with prostaglandin E1 injection therapy is sporadic and unpredictable. Patients with initial penile scarring do not have a higher incidence of further scarring.
机译:目的:我们试图确定使用前列腺素E1注射疗法的患者阴茎瘢痕形成的危险因素。材料与方法:回顾性分析了92例使用前列腺素E1治疗的患者的记录。采用统计学方法,比较有疤痕形成(15)和无疤痕形成(77)的患者。结果:两组的随访时间,注射频率,每次注射前列腺素E1剂量,注射总数或总前列腺素E1剂量之间均无显着差异。最初阴茎瘢痕形成的患者前列腺素E1进一步瘢痕形成的发生率没有明显增加。结论:前列腺素E1注射疗法对阴茎瘢痕形成是零星的且不可预测的。最初有阴茎瘢痕形成的患者没有进一步的瘢痕形成的可能性更高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号